Business

Indicative Announcement on the Phase Ⅲ Clinical Trial of Recombinant Anti-Human IL-17A/F Humanized Monoclonal Antibody Injection Reaching the Primary Study Endpoint

Indicative Announcement on the Phase Ⅲ Clinical Trial of Recombinant Anti-Human IL-17A/F Humanized Monoclonal Antibody Injection Reaching the Primary Study Endpoint

articleJoincare Pharmaceutical Group Industry Co., Ltd. Class AJuly 21, 20254/news/indicative-announcement-on-the-phase-clinical-trial-of-recombinant-anti-human-il-17af-humanized-monoclonal-antibody-injection-reaching-the-primary-study-endpoint
Indicative Announcement on the Phase Ⅲ Clinical Trial of Recombinant Anti-Human IL-17A/F Humanized Monoclonal Antibody Injection Reaching the Primary Study Endpoint

About this update from Joincare Pharmaceutical Group Industry Co., Ltd. Class A

Indicative Announcement on the Phase Ⅲ Clinical Trial of Recombinant Anti-Human IL-17A/F Humanized Monoclonal Antibody Injection Reaching the Primary Study EndpointThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Joincare Pharmaceutical Group Industry Co., Ltd. Class A